Evaluating different routes of extracellular vesicle administration for cranial therapies.

IF 1.4 Q4 ONCOLOGY Journal of Cancer Metastasis and Treatment Pub Date : 2020-01-01 Epub Date: 2020-06-18 DOI:10.20517/2394-4722.2020.22
Pericles Ioannides, Erich Giedzinski, Charles L Limoli
{"title":"Evaluating different routes of extracellular vesicle administration for cranial therapies.","authors":"Pericles Ioannides,&nbsp;Erich Giedzinski,&nbsp;Charles L Limoli","doi":"10.20517/2394-4722.2020.22","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Human stem cell-derived extracellular vesicles (EV) provide many advantages over cell-based therapies for the treatment of functionally compromised tissue beds and organ sites. Here we aimed to highlight multiple administration routes for the potential treatment of various forms of brain injury.</p><p><strong>Methods: </strong>Human neural stem cell-derived EV were isolated from conditioned media and administered via three distinct routes: intrahippocampal transplantation, retro-orbital vein injection, and intranasal. EV were administered after which brains were evaluated to determine the capability of EV to translocate into normal tissue.</p><p><strong>Results: </strong>Data showed no significant differences in the amount of EV able to translocate across the brain, indicating the functional equivalence of each administration route to effectively deliver EV to the brain parenchyma.</p><p><strong>Conclusion: </strong>Findings show that both systemic administration routes (retro-orbital vein or intranasal delivery) afforded effective penetrance and perfusion of EV throughout the brain in a minimally invasive manner, and point to a translationally tractable option for treating certain neurological disorders including those resulting from cranial irradiation procedures.</p>","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"6 15","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281946/pdf/","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Metastasis and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/2394-4722.2020.22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/6/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 11

Abstract

Aim: Human stem cell-derived extracellular vesicles (EV) provide many advantages over cell-based therapies for the treatment of functionally compromised tissue beds and organ sites. Here we aimed to highlight multiple administration routes for the potential treatment of various forms of brain injury.

Methods: Human neural stem cell-derived EV were isolated from conditioned media and administered via three distinct routes: intrahippocampal transplantation, retro-orbital vein injection, and intranasal. EV were administered after which brains were evaluated to determine the capability of EV to translocate into normal tissue.

Results: Data showed no significant differences in the amount of EV able to translocate across the brain, indicating the functional equivalence of each administration route to effectively deliver EV to the brain parenchyma.

Conclusion: Findings show that both systemic administration routes (retro-orbital vein or intranasal delivery) afforded effective penetrance and perfusion of EV throughout the brain in a minimally invasive manner, and point to a translationally tractable option for treating certain neurological disorders including those resulting from cranial irradiation procedures.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估不同途径的细胞外囊泡给药颅内治疗。
目的:人类干细胞来源的细胞外囊泡(EV)在治疗功能受损的组织床和器官部位方面提供了许多优于细胞疗法的优势。在这里,我们的目的是强调多种给药途径的潜在治疗各种形式的脑损伤。方法:从条件培养基中分离人类神经干细胞衍生的EV,并通过三种不同的途径给予:海马内移植、眶后静脉注射和鼻内注射。给药后对大脑进行评估,以确定EV转移到正常组织的能力。结果:数据显示,各给药途径在脑内EV转运量上无显著差异,说明各给药途径在将EV有效递送至脑实质方面功能等效。结论:研究结果表明,两种全身给药途径(眶后静脉或鼻内给药)都能以微创方式有效地渗透和灌注EV到整个大脑,并为治疗某些神经系统疾病提供了一种翻译上易于处理的选择,包括那些由颅照射程序引起的疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.20
自引率
5.30%
发文量
460
期刊最新文献
Thermal ablation of metastatic disease to the musculoskeletal system Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma? Advanced breast cancer metastasized in the brain: treatment standards and innovations. Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? An update on clinical trials for chemoprevention of human skin cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1